Main Article Content
Bioequivalence of 50 mg and 100 mg of the generic atenolol tablets (Tenolol®, Siam
Pharmaceutical) were compared to the innovative product (Tenormin®, Zeneca Limited). Each preparation was administered to twelve healthy Thai volunteers according to a randomized balance two-way crossover design with one week washout period. After drug administration, serial blood samples were collected over a period of 24 hr and 30 hr for 50 mg and 100 mg atenolol preparations, respectively. Atenolol plasma concentrations were measured using HPLC technique with fluorometric detection. Pharmacokinetic parameters were analyzed by noncompartrnental pharmacokinetic method using TOPFIT. The means and parametric 90% confidence intervals of the ratio (Tenolol®/Tenormin®) of Cmax, and AUC0-∞ were 1.17 (1.00-1.34) and 1.08 (0.96-1.19), as well as 0.94 (0.77-1.12) and 0.98 (0.84-1.14) for 50 mg and 100 mg doses, respectively. These values complied with the acceptable bioequivalence ranges of 0.7-1.43 and 0.8- 1.25 for the ratios (Test/Reference) of Cmax and AUC0-∞ respectively. The mean differences of Tmax (Tenolol®-Tenormin®) were -0.33 and -0.06 hr for 50 mg and 100 mg, respectively. These values were well within the stipulated bioequivalence ranges of Tm" differences (± 20% of the Tm" of the reference formulation) of ± 0.58 hr and ± 0.78 hr for 50 mg and 100 mg preparations, respectively. Based on the result of this study, 50 mg and 100 mg of Tenolol® were bioequivalent to the innovator (Tenormin®) with respect to the extent and rate of absorption.
Upon acceptance of an article, the Pharmacological and Therapeutic Society of Thailand will have exclusive right to publish and distribute the article in all forms and media and grant rights to others. Authors have rights to use and share their own published articles.